EuropaBio’s Most Innovative Biotechs 2014

September 4, 2014
The Pharm Exec staff

Pharmaceutical Executive

EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”.

EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium.

Shortlisted are: 

Autifony (London, UK): A healthcare biotech based at Imperial College London, focused on the development of high value novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.

Bio-on (Bologna, Italy): Bio-on works in industrial biotechnology applied to widely used materials, creating natural products and solutions based on renewable resources or on agricultural processing waste material.

Biosyntia (Horshølm, Denmark): An industrial biotech SME, providing unique fermentation solutions to chemical manufacturing companies.

Erytech Pharma (Lyon, France): A biopharmaceutical company developing an innovative concept to starve cancer cells in specific essential nutrients, and quickly induce their death without impairing any healthy cells. 

to-BBB (Leiden, The Netherlanda): A biotech developing novel treatments for patients with devastating brain diseases. Its lead clinical programs target multiple types of brain cancers, including brain metastases from breast cancer, as well as neuro-inflammatory diseases.

This year’s award ceremony reportedly has a focus on financing, with the European Investment Bank presenting its Growth Financing Facility for funding innovative companies in the EU, and the European Commission illustrating its SME Instrument under Horizon 2020.  

Click here for further information.

Related Content:

News